Karin Wernicke‐Panten

Author

Also Known As

K Wernicke-Panten, K. Wernicke-Panten, K. Wernicke‐Panten, KARIN WERNICKE-PANTEN, Karin Wernicke-Panten, Karin Wernicke‐Panten, Κ. Wernicke-Panten

Publications

900

Citations

H-Index

Concepts

All Affiliations

Sanofi (France)Sanofi (Germany)University of Colorado Denver Sanofi (United States)Seinäjoki University of Applied Sciences

About

Karin Wernicke‐Panten is an author at Sanofi (France) specializing in diabetes, pharmacotherapy, and metabolic syndrome.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	162
2	Diabetes	1	1	162
3	Pharmacology	1	1	162
4	Metabolic Syndrome	1	1	162
5	Pharmacotherapy	1	1	162

Karin Wernicke‐Panten

Publications

696

Citations

H-Index

Page 1

	Year	Citations
Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo Thomas Dirschka, Peter Radny, R. Dominicus, British Journal of Dermatology	2011	178
Long-Term Treatment of Type 2 Diabetic Patients with the New Oral Antidiabetic Agent Glimepiride (Amaryl®): A Double-Blind Comparison with Glibenclamide K. Draeger, Karin Wernicke‐Panten, H.-J. Lomp, Hormone and Metabolic Research Metabolic SyndromeHigher DosageDiabetes ManagementDiabetesPharmacology	1996	162
Comparative Trial Between Insulin Glargine and NPH Insulin in Children and Adolescents with Type I Diabetes Mellitus Ε. Schoenle, J. Van Dyk, Karin Wernicke‐Panten, Journal of Pediatric Endocrinology and Metabolism	2002	121
Long‐term (6 and 12 months) follow‐up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF‐200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis Thomas Dirschka, Peter Radny, R. Dominicus, British Journal of Dermatology	2012	98
Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 1 Diabetes Also Using Insulin Glargine—SORELLA 1 Study Satish K. Garg, Karin Wernicke‐Panten, Maria Rojeski, Diabetes Technology & Therapeutics	2017	32
Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes Philip Home, Karl-Michael Derwahl, M. Ziemen, Diabetes Technology & Therapeutics	2018	27
Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1) Satish K. Garg, Karin Wernicke‐Panten, Marek Wardęcki, Diabetes Technology & Therapeutics	2019	27
Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study Karl-Michael Derwahl, Timothy S. Bailey, Karin Wernicke‐Panten, Diabetes Technology & Therapeutics	2017	24
Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump James Thrasher, Howard K. Surks, Irene Nowotny, Journal of Diabetes Science and Technology	2018	16
Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial Satish K. Garg, Karin Wernicke‐Panten, Marek Wardęcki, Diabetes Technology & Therapeutics	2020	11

Page 1